Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study

PURPOSE: This study aimed to investigate the incidence rate and risk factors for hepatic encephalopathy (HE) among unresectable hepatocellular carcinoma (uHCC) patients with liver cirrhosis who received sorafenib or lenvatinib treatment. PATIENTS AND METHODS: uHCC patients with cirrhosis who receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Bowen, Zhang, Linzhi, Cheng, Jiamin, Wu, Tong, Lei, Jin, Yang, Xu, Zhang, Rongling, Safadi, Rifaat, Li, Yinyin, Si, Tongguo, Lu, Yinying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805705/
https://www.ncbi.nlm.nih.gov/pubmed/36597443
http://dx.doi.org/10.2147/DDDT.S386829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805705/
https://www.ncbi.nlm.nih.gov/pubmed/36597443
http://dx.doi.org/10.2147/DDDT.S386829

Ejemplares similares